Hikma Pharmaceuticals PLC (LON:HIK – Get Rating) announced a dividend on Thursday, August 4th, Upcoming.Co.Uk reports. Stockholders of record on Thursday, August 18th will be given a dividend of $0.19 per share on Monday, September 19th. This represents a dividend yield of 0.89%. The ex-dividend date of this dividend is Thursday, August 18th. The official announcement can be seen at this link.
Hikma Pharmaceuticals Price Performance
Hikma Pharmaceuticals stock opened at GBX 1,604.50 ($19.66) on Friday. Hikma Pharmaceuticals has a 12 month low of GBX 1,459.50 ($17.88) and a 12 month high of GBX 2,674 ($32.77). The company has a debt-to-equity ratio of 34.29, a current ratio of 2.06 and a quick ratio of 1.31. The business has a 50 day simple moving average of GBX 1,649.71 and a 200-day simple moving average of GBX 1,851.18. The stock has a market capitalization of £3.53 billion and a PE ratio of 1,084.12.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the company. Barclays cut Hikma Pharmaceuticals to an “equal weight” rating and cut their price target for the stock from GBX 2,250 ($27.57) to GBX 1,750 ($21.44) in a research note on Friday. JPMorgan Chase & Co. cut Hikma Pharmaceuticals to a “neutral” rating and cut their price objective for the stock from GBX 2,900 ($35.53) to GBX 1,900 ($23.28) in a research report on Wednesday, May 25th. Finally, Morgan Stanley reiterated an “equal weight” rating on shares of Hikma Pharmaceuticals in a research report on Wednesday, May 11th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of GBX 2,291.67 ($28.08).
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.